Cargando…
Effect of cyclooxygenase inhibitor use on immunotherapy efficacy in non‐small cell lung cancer
BACKGROUND: A synergistic effect of cyclooxygenase inhibitors (COX‐I) and immune checkpoint inhibitors (ICIs) has been suggested. However, the impact of COX‐I on the efficacy of ICIs is unclear. Here, we aimed to evaluate the relationship between COX‐I use and the efficacy of ICI in patients with no...
Autores principales: | Kanai, Osamu, Ito, Takanori, Saito, Zentaro, Yamamoto, Yuki, Fujita, Kohei, Okamura, Misato, Hashimoto, Masayuki, Nakatani, Koichi, Sawai, Satoru, Mio, Tadashi |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley & Sons Australia, Ltd
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7952791/ https://www.ncbi.nlm.nih.gov/pubmed/33559253 http://dx.doi.org/10.1111/1759-7714.13845 |
Ejemplares similares
-
Efficacy and safety of immune checkpoint inhibitors in patients with non‐small cell lung cancer aged 80 years or older
por: Saito, Zentaro, et al.
Publicado: (2021) -
Incidence of Active Tuberculosis in Lung Cancer Patients Receiving Immune Checkpoint Inhibitors
por: Fujita, Kohei, et al.
Publicado: (2020) -
Small cell transformation of non‐small cell lung cancer under immunotherapy: Case series and literature review
por: Imakita, Takuma, et al.
Publicado: (2021) -
Retreatment with anti‐PD‐1 antibody in non‐small cell lung cancer patients previously treated with anti‐PD‐L1 antibody
por: Fujita, Kohei, et al.
Publicado: (2019) -
Pleural involvement of diffuse large B-cell lymphoma mimicking malignant pleural mesothelioma
por: Ito, Takanori, et al.
Publicado: (2020)